OPKO to sell BioReference lab testing unit to LabCorp for $722M cash plus up to $150M 4Kscore earnout

OPKO HEALTH, INC.

LabCorp (Buyer) to pay OPKO/BioReference $722,000,000 in cash at closing, subject to upward or downward adjustment based on Business revenues at closing; no financing condition.
Additional earnout of up to $150,000,000 in cash over up to ten years tied to LabCorp's revenue from the 4Kscore prostate cancer test.
Assets sold include BioReference clinical/anatomic pathology testing in clinical and women's health, urology and corrections, plus the 4Kscore Test and its FDA PMA and trademark.
Closing conditioned on HSR antitrust clearance; outside date April 14, 2027, extendable by mutual agreement. Buyer owes a $28,880,000 termination fee if required government approvals fail.
OIG Determination was obtained as of the October 14, 2026 agreement date; Seller agreed to a no-shop covering alternative transactions.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.